SUIG · SUI Group Holdings Ltd.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents a one-time equity grant as part of the Reporting Person's non-management director compensation, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents a one-time equity grant as part of the Reporting Person's non-management director compensation, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents a one-time equity grant as part of the Reporting Person's non-management director compensation, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents a one-time equity grant as part of the Reporting Person's non-management director compensation, effective July 6, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon his appointment to the Issuer's Board of Directors, effective January 5, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on July 5, 2026, 25% of each tranche of the warrants will become exercisable on January 5, 2027, 25% of each tranche of the warrants will become exercisable on July 5, 2027, and 25% of each tranche of the warrants will become exercisable on January 5, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon his appointment to the Issuer's Board of Directors, effective January 5, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on July 5, 2026, 25% of each tranche of the warrants will become exercisable on January 5, 2027, 25% of each tranche of the warrants will become exercisable on July 5, 2027, and 25% of each tranche of the warrants will become exercisable on January 5, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon his appointment to the Issuer's Board of Directors, effective January 5, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on July 5, 2026, 25% of each tranche of the warrants will become exercisable on January 5, 2027, 25% of each tranche of the warrants will become exercisable on July 5, 2027, and 25% of each tranche of the warrants will become exercisable on January 5, 2028.

Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon his appointment to the Issuer's Board of Directors, effective January 5, 2026.

The warrants vest as follows: 25% of each tranche of the warrants become exercisable on July 5, 2026, 25% of each tranche of the warrants will become exercisable on January 5, 2027, 25% of each tranche of the warrants will become exercisable on July 5, 2027, and 25% of each tranche of the warrants will become exercisable on January 5, 2028.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Polinsky being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Polinsky is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Geraci being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Geraci is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Geraci being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Geraci is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Polinsky being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Polinsky is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Geraci being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Geraci is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The warrants are exercisable for a period of five years. The warrants will vest over a period of 24 months starting six months from the issue date in four equal instalments (being 25% every six months), subject to Mr. Polinsky being employed by Mill City Ventures III, LP at each respective vesting date. Notwithstanding the foregoing, in the event that Mr. Polinsky is terminated other than for cause or resigns for good reason (as defined in the individual's employment agreement), the vesting of all of such warrants will immediately accelerate and be fully vested as of the date of such termination.

The reported transaction reflects shares transferred to the reporting person's ex-spouse pursuant to a marital-dissolution decree. The securities owned by the ex-spouse are not beneficially owned by the reporting person.

The reported transaction reflects shares transferred to the reporting person's ex-spouse pursuant to a marital-dissolution decree. The securities owned by the ex-spouse are not beneficially owned by the reporting person.

Share figure includes 30,850 common shares previously reported as held indirectly, but which have been determined to be held directly by the reporting person.